SEC Form 4 · accession 0001562180-18-005031

ARRAY BIOPHARMA INC · ARRY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer

Period of report

Dec 14, 2018

Accepted (ET)

Dec 18, 2018 · 7:49 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001100412

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 16, 2018	M	23,346	$0.00	A	245,644	D
Common Stock^F2	Dec 16, 2018	F	10,378	$15.97	D	235,266	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F3	$0.00	Dec 14, 2018	A	48,250	A	—	Dec 20, 2022	Common Stock	48,250	48,250	D
Stock Option (Right to Buy)^F4	$15.97	Dec 14, 2018	A	289,500	A	—	Dec 16, 2028	Common Stock	289,500	289,500	D
Restricted Stock Units^F5	$0.00	Dec 16, 2018	M	11,284	D	—	Dec 16, 2020	Common Stock	11,284	22,570	D
Restricted Stock Units^F5	$0.00	Dec 16, 2018	M	12,062	D	—	Dec 17, 2021	Common Stock	12,062	36,188	D

F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs.
F2Represents shares withheld to satisfy tax withholding obligations of the reporting person.
F3RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019.
F4The options vest in four equal annual installments beginning on December 16, 2019.
F5The RSUs vested and were settled in common stock on December 16, 2018.